Literature DB >> 9421461

Role of inducible nitric oxide synthase in regulation of pulmonary vascular tone in the late gestation ovine fetus.

R L Rairigh1, T D Le Cras, D D Ivy, J P Kinsella, G Richter, M P Horan, I D Fan, S H Abman.   

Abstract

Nitric oxide (NO) produced by NO synthase (NOS) modulates fetal pulmonary vascular tone and contributes to the fall in pulmonary vascular resistance (PVR) at birth. Although the inducible (type II) NOS isoform is present in human and rat fetal lungs, it is uncertain whether type II NOS activity contributes to vascular NO production in the fetal lung. To determine whether type II NOS is present in the ovine fetal lung and to study the potential contribution of type II NOS on the regulation of basal PVR in the fetus, we measured the hemodynamic effects of three selective type II NOS antagonists: aminoguanidine (AG), 2-amino-5,6-dihydro-6-methyl-4H-1,3 thiazine (AMT), and S-ethylisothiourea (EIT). Studies were performed after at least 72 h of recovery from surgery in 19 chronically prepared fetal lambs (133+/-3 d; 147 d, term). Brief intrapulmonary infusions of AG (140 mg), AMT (0.12 mg), and EIT (0.12 mg) increased basal PVR by 82, 69, and 77%, respectively (P < 0.05). The maximum increase in PVR occurred within 20 min, but often persisted up to 80 min. These agents also increased mean aortic pressure but did not alter the pressure gradient between the pulmonary artery and aorta, suggesting little effect on tone of the ductus arteriosus. Acetylcholine-induced pulmonary vasodilation remained intact after treatment with selective type II NOS antagonists, but not after treatment with the nonselective NOS blocker, nitro-L-arginine. Using Northern blot analysis with poly(A)+ RNA, we demonstrated the presence of two mRNA transcripts for type II NOS (4.1 and 2.6 kb) in the fetal lung. We conclude that the type II NOS isoform is present in the ovine fetal lung, and that selective type II NOS antagonists increase PVR and systemic arterial pressure in the late-gestation fetus. We speculate that type II NOS may play a physiological role in the modulation of vascular tone in the developing fetal lung.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9421461      PMCID: PMC508535          DOI: 10.1172/JCI1228

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples.

Authors:  P Chomczynski
Journal:  Biotechniques       Date:  1993-09       Impact factor: 1.993

2.  Lipopolysaccharide treatment in vivo induces widespread tissue expression of inducible nitric oxide synthase mRNA.

Authors:  S Liu; I M Adcock; R W Old; P J Barnes; T W Evans
Journal:  Biochem Biophys Res Commun       Date:  1993-11-15       Impact factor: 3.575

3.  Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization.

Authors:  L Kobzik; D S Bredt; C J Lowenstein; J Drazen; B Gaston; D Sugarbaker; J S Stamler
Journal:  Am J Respir Cell Mol Biol       Date:  1993-10       Impact factor: 6.914

4.  Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic process.

Authors:  J A Corbett; A Mikhael; J Shimizu; K Frederick; T P Misko; M L McDaniel; O Kanagawa; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

5.  Aminoguanidine selectively inhibits inducible nitric oxide synthase.

Authors:  M J Griffiths; M Messent; R J MacAllister; T W Evans
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

6.  Effects of oxygen and exogenous L-arginine on EDRF activity in fetal pulmonary circulation.

Authors:  J A McQueston; D N Cornfield; I F McMurtry; S H Abman
Journal:  Am J Physiol       Date:  1993-03

7.  Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases.

Authors:  A J Farrell; D R Blake; R M Palmer; S Moncada
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

8.  In vivo pharmacological evaluation of two novel type II (inducible) nitric oxide synthase inhibitors.

Authors:  W R Tracey; M Nakane; F Basha; G Carter
Journal:  Can J Physiol Pharmacol       Date:  1995-05       Impact factor: 2.273

9.  In vivo treatment with endotoxin induces nitric oxide synthase in rat main pulmonary artery.

Authors:  M J Griffiths; S Liu; N P Curzen; M Messent; T W Evans
Journal:  Am J Physiol       Date:  1995-03

10.  Novel potent and selective inhibitors of inducible nitric oxide synthase.

Authors:  M Nakane; V Klinghofer; J E Kuk; J L Donnelly; G P Budzik; J S Pollock; F Basha; G W Carter
Journal:  Mol Pharmacol       Date:  1995-04       Impact factor: 4.436

View more
  5 in total

1.  Selective type 5 phosphodiesterase inhibition alters pulmonary hemodynamics and lung liquid production in near-term fetal lambs.

Authors:  Robert C Dukarm; Robin H Steinhorn; James A Russell; Satyan Lakshminrusimha; Daniel Swartz; James J Cummings
Journal:  J Appl Physiol (1985)       Date:  2005-08-25

2.  Erythropoietin and hypoxia increase erythropoietin receptor and nitric oxide levels in lung microvascular endothelial cells.

Authors:  Bojana B Beleslin-Čokić; Vladan P Cokić; Li Wang; Barbora Piknova; Ruifeng Teng; Alan N Schechter; Constance T Noguchi
Journal:  Cytokine       Date:  2011-02-15       Impact factor: 3.861

Review 3.  The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension.

Authors:  Evangelos D Michelakis
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

4.  Cyclic stretch induces inducible nitric oxide synthase and soluble guanylate cyclase in pulmonary artery smooth muscle cells.

Authors:  Monica R Shah; Stephen Wedgwood; Lyubov Czech; Gina A Kim; Satyan Lakshminrusimha; Paul T Schumacker; Robin H Steinhorn; Kathryn N Farrow
Journal:  Int J Mol Sci       Date:  2013-02-21       Impact factor: 5.923

5.  Proapoptotic effects of novel pentabromobenzylisothioureas in human leukemia cell lines.

Authors:  Mirosława Koronkiewicz; Zdzisław Chilmonczyk; Zygmunt Kazimierczuk
Journal:  Med Chem Res       Date:  2011-11-11       Impact factor: 1.965

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.